It’s May already, and Optimum Strategic Communications and its clients have had their foot on the gas this week as we head into the summer months. Poolbeg signs exclusive option agreement to acquire orphan drug candidate for Behçet’s Disease Poolbeg Pharma, a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases […]
The current optimistic mood in biotech was reflected in a string of positive announcements from Optimum and its clients. SynOx completes $75m Series B financing to fund cancer mAb SynOx Therapeutics Limited, the late-stage clinical biopharmaceutical company, on Monday announced the close of a $75m Series B financing. The financing was co-led by Forbion, HealthCap […]
The great and good of Europe’s biotech scene descended on London on Wednesday and Thursday, with over 370 delegates from leading and upcoming drug discovery and technology companies in the UK, Nordic and other European regions attending the main event in County Hall. With over 90 investment firms participating and 36 funding pitches, this 20th […]
Summer is just around the corner and there was real optimism in the air this week as Optimum’s clients looked forward to 2024, with the conference season about to start. Medicxi Announces £40m investment in D3 Bio Medicxi, a leading European life sciences investment firm, on Monday announced an investment of $40 million in D3 […]
It was a short week after the Easter break but there was plenty of positive news from Optimum’s clients with summer just around the corner. Novo Holdings Asia Investment on the up Novo Holdings’ Asia Investments team on Wednesday published its annual review – a year of developing and building for long-term results. During 2023, […]
